Active Hexose Correlated Compound (AHCC) Inhibits the Proliferation of Ovarian Cancer Cells by Suppressing Signal Transducer and Activator of Transcription 3 (STAT3) Activation

References

• Webb PM and Jordan SJ: Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 41, 3–14, 2017.
   PubMed Web of Science ®Google Scholar
• Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, et al.: Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1), S161–S192, 2006.
   PubMed Web of Science ®Google Scholar
• Banerjee S and Kaye SB: New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res 19, 961–968, 2013.
   PubMed Web of Science ®Google Scholar
• Ahn KS, Sethi G, Sung B, Goel A, Ralhan R, et al.: Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res 68, 4406–4415, 2008.
   PubMed Web of Science ®Google Scholar
• Li F, Fernandez PP, Rajendran P, Hui KM, and Sethi G: Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett 292, 197–207, 2010.
   PubMed Web of Science ®Google Scholar
• Zhang T, Li S, Li J, Yin F, Hua Y, et al.: Natural product pectolinarigenin inhibits osteosarcoma growth and metastasis via SHP-1-mediated STAT3 signaling inhibition. Cell Death Dis 7, e2421, 2016.
   PubMed Web of Science ®Google Scholar
• Siveen KS, Sikka S, Surana R, Dai X, Zhang J, et al.: Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta 1845, 136–154, 2014.
   PubMed Web of Science ®Google Scholar
• Hirose A, Sato E, Fujii H, Sun B, Nishioka H, et al.: The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice. Toxicol Appl Pharmacol 222, 152–158, 2007.
   PubMed Web of Science ®Google Scholar
• Shigama K, Nakaya A, Wakame K, Nishioka H, and Fujii H: Alleviating effect of active hexose correlated compound (AHCC) for anticancer drug-induced side effects in non-tumor-bearing mice. J Exp Ther Oncol 8, 43–51, 2009.
   PubMedGoogle Scholar
• Gao Y, Zhang D, Sun B, Fujii H, Kosuna K, et al.: Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses. Cancer Immunol Immunother 55, 1258–1266, 2006.
   PubMed Web of Science ®Google Scholar
• Miura T, Kitadate K, Nishioka H, and Wakame K: Basic and clinical studies on active hexose correlated compound. In: Biotechnology in Functional Foods and Nutraceuticals. New York: CRC Press, 2010, pp. 51–59.
   Google Scholar
• Kidd PM: The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev 5, 4–27, 2000.
   PubMedGoogle Scholar
• Hunter R, Fujii H, Wakame K, Gaikwad A, Wolf J, et al.: Evaluation of active hexose correlated compound (AHCC) in combination with pegylated liposomal doxorubicin for treatment of ovarian cancer. Int J Appl Res Nat Prod 4, 6–11, 2011.
   Google Scholar
• Cai L, Zhang G, Tong X, You Q, An Y, et al.: Growth inhibition of human ovarian cancer cells by blocking STAT3 activation with small interfering RNA. Eur J Obstet Gynecol Reprod Biol 148, 73–80, 2010.
   PubMed Web of Science ®Google Scholar
• Landen CN, Jr., Lin YG, Armaiz Pena GN, Das PD, Arevalo JM, et al.: Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res 67, 10389–10396, 2007.
   PubMed Web of Science ®Google Scholar
• Hirano T, Ishihara K, and Hibi M: Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19, 2548–2556, 2000.
   PubMed Web of Science ®Google Scholar
• Harada D, Takigawa N, and Kiura K: The role of STAT3 in non-small cell lung cancer. Cancers (Basel) 6, 708–722, 2014.
   PubMed Web of Science ®Google Scholar
• Chen SH, Murphy DA, Lassoued W, Thurston G, Feldman MD, et al.: Activated STAT3 is a mediator and biomarker of VEGF endothelial activation. Cancer Biol Therm 7, 1994–2003, 2008.
   PubMed Web of Science ®Google Scholar
• Beaufort CM, Helmijr JC, Piskorz AM, Hoogstraat M, Ruigrok-Ritstier K, et al.: Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS One 9, e103988, 2014.
   PubMed Web of Science ®Google Scholar
• Su JC, Chiang HC, Tseng PH, Tai WT, Hsu CY, et al.: RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells. Carcinogenesis 35, 2807–2814, 2014.
   PubMed Web of Science ®Google Scholar
• Ekor M: The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol 4, 177, 2014.
   PubMed Web of Science ®Google Scholar
• Matsui Y, Uhara J, Satoi S, Kaibori M, Yamada H, et al.: Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol 37, 78–86, 2002.
   PubMed Web of Science ®Google Scholar
• Suenaga S, Kuramitsu Y, Kaino S, Maehara S, Maehara Y, et al.: Active hexose-correlated compound down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine. Anticancer Res 34, 141–146, 2014.
   PubMed Web of Science ®Google Scholar
• Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, et al.: Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 59, 5059–5063, 1999.
   PubMed Web of Science ®Google Scholar
• Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, et al.: Stat3 as an oncogene. Cell 98, 295–303, 1999.
   PubMed Web of Science ®Google Scholar
• Al Zaid Siddiquee K and Turkson J: STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 18, 254–267, 2008.
   PubMed Web of Science ®Google Scholar
• Masciocchi D, Gelain A, Villa S, Meneghetti F, and Barlocco D: Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy. Future Med Chem 3, 567–597, 2011.
   PubMed Web of Science ®Google Scholar
• Buettner R, Mora LB, and Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8, 945–954, 2002.
   PubMed Web of Science ®Google Scholar
• Wu C, Sun M, Liu L, and Zhou GW: The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 306, 1–12, 2003.
   PubMed Web of Science ®Google Scholar
• Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, et al.: Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA 101, 10602–10607, 2004.
   PubMed Web of Science ®Google Scholar